[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632675":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":24,"locations":30,"responsibleParty":47,"collaborators":12,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":12,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":33,"whyStopped":12,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Tanta University","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"control group","NO_INTERVENTION","this group will include 23 patients who will receive their traditional therapy of RA for 3 months.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Nicorandil group","ACTIVE_COMPARATOR","this group will include 23 patients who will receive 5 mg nicorandil twice daily before meals plus the traditional therapy of RA for 3 months.",[18],"Drug: Nicorandil 5 MG Oral Tablet",[20],{"type":21,"name":22,"description":22,"armGroupLabels":23,"otherNames":12},"DRUG","Nicorandil 5 MG Oral Tablet",[14],[25],{"name":26,"role":27,"phone":28,"phoneExt":12,"email":29},"Karim Abu Elfath Hussein","CONTACT","+201141332986","Kareem_hussein@pharm.tanta.edu.eg",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":12,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Tanta university","RECRUITING","Tanta","Gharbia Governorate","Egypt","EG",{"type":39,"coordinates":40},"Point",[41,42],31.00192,30.78847,{"lat":42,"lon":41},[45],{"name":46,"role":27,"phone":28,"phoneExt":12,"email":29},"Karim Abu elfath Hussein",{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"PRINCIPAL_INVESTIGATOR","Karim Abu El Fath Hussein Abd El Hakim","demonstrator at clinical pharmacy department, faculty of pharmacy, Tanta University","100632675","phase-3-nicorandil-as-anti-inflammatory-in-rheumatoid-arthritis-100632675",false,"NCT07516769","Nicorandil as Anti-inflammatory in Rheumatoid Arthritis","Clinical Study Evaluating the Effect of Nicorandil as Anti-inflammatory and Immune Modulatory in Patients With Rheumatoid Arthritis","RA","Inclusion Criteria:\n\n* Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology\u002FEuropean League Against Rheumatism (ACR\u002FEULAR) i.e., 28 joints disease activity score (DAS-28) \\>2.6.\n* Patients receiving the conventional DMARDs\n\nExclusion Criteria:\n\n* Patients with heart disease (congestive heart failure, arrhythmia and ischemic heart disease), diabetes, active infection, and other illness except rheumatoid arthritis.\n* Patients with severe renal and hepatic dysfunction. - Patients receiving biological DMARDs.\n* Patients receiving oral prednisolone greater than 15mg\u002Fday.\n* Patients with hypersensitivity to study medications.\n* Patients using antioxidants.\n* Pregnant and lactating females.","ALL","18 Years","70 Years",{"count":63,"type":64},46,"ESTIMATED","INTERVENTIONAL",[67],"PHASE3","This study aims to evaluate the possible efficacy and safety of nicorandil as anti-inflammatory in managing patients with active rheumatoid arthritis.",[70],"Rhumatoid Arthisis",[70,72],"Nicorandil","2026-06-16",{"date":75,"type":76},"2026-06-18","ACTUAL",{"date":78,"type":76},"2024-11-01",{"date":80,"type":64},"2027-04",{"name":5,"class":6},1]